Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.
about
Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.The transcriptional regulation of the human CYP2C genesGemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavirA phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavirMechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19Use of antineoplastic agents in patients with cancer who have HIV/AIDS.Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.Drug interactions in the management of HIV infection.Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects.Safety of lopinavir/ritonavir for the treatment of HIV-infection.Treatment of dyslipidaemia in HIV-infected persons.Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the InternatiThe impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study.Interaction between lopinavir/ritonavir and warfarin.Drug interactions in the management of HIV infection: an update.Drugs as CYP3A probes, inducers, and inhibitors.Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.Induction effects of ritonavir: implications for drug interactions.Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Enzyme induction with antiepileptic drugs: cause for concern?Induction of cytochrome P450 enzymes: a view on human in vivo findings.A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine ProductsSeizure management in a complex hospice patient.Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject.Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR.
P2860
Q33400092-E7E00098-F71B-4185-BF35-F4BC32C8D92AQ33597311-A44269C9-94CD-457A-B65A-701EBAB292C6Q33625135-EF92C965-9709-4BB8-B782-9C76C26039ACQ33899829-6F09368C-C047-435C-8C5F-FF254D26EDC9Q34633457-C37D8144-5BB8-483C-A34F-691019C35B6FQ35057326-ACA8AADD-1B15-4D98-8BC3-E53D739565BBQ35211432-18455C50-7D11-4AB0-BCC0-613E172EABE1Q35932561-2FE3F93D-49F3-4AB2-A629-CDF6366D21E3Q36040272-F12F2593-A6CC-4AEB-B91A-4ECDA896B401Q36066083-3A3EC584-684F-427C-9134-A2AFA0099ABFQ36126286-1AF23D3B-7A26-455D-B849-F908FDC70371Q36150530-DF38EB3C-4B61-40B7-A072-6AA75F06F5EEQ36222023-C339E653-2536-4852-98E9-7E66A27C4A00Q36304546-66E1BD6A-F853-4A1B-81F6-25A452FAA70FQ36428784-E782DE58-D333-45FD-8EFC-BC0F7B07BC0BQ36910151-67FE2743-8D91-4D8F-9CC6-795D6E8B4258Q37000733-C11BF9EF-B816-4C92-9443-6460DACD7E23Q37023996-0A22F1FB-E335-44EF-9E21-0EE1101C4BC8Q37052827-07BD60E2-1206-4987-B49A-75A3D5C65555Q37199533-2898EB4E-E4E3-49FC-9AEF-98C8DB45E887Q37669678-1F711EBE-9AD8-4974-9678-7555BFDB1F13Q37973439-99EE0B49-414C-4531-B0EE-9C7FD41356E2Q38028549-B866B74E-2BAB-492C-AA6E-1C0FB74D954FQ38046892-21C435D0-B803-4DA6-A0CE-DCCD716341B2Q38057372-2730A29E-A602-4ACC-A6B9-D60D919776EAQ38513275-3062B937-47B3-4BC3-A944-16116FD7BEA3Q43117585-3FA29E24-0FA7-444D-A2D8-732A33B51DBFQ46623386-D42C3989-3C4B-4F2B-89EA-0219741CA47EQ46812234-64A724A5-2FE4-4236-8CB5-4281956D4543Q47909730-23FFD5A9-FBFC-44E5-AB56-F654704270B6
P2860
Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Coadministration of lopinavir/ ...... gh cytochrome P-450 induction.
@en
Coadministration of lopinavir/ ...... gh cytochrome P-450 induction.
@nl
type
label
Coadministration of lopinavir/ ...... gh cytochrome P-450 induction.
@en
Coadministration of lopinavir/ ...... gh cytochrome P-450 induction.
@nl
prefLabel
Coadministration of lopinavir/ ...... gh cytochrome P-450 induction.
@en
Coadministration of lopinavir/ ...... gh cytochrome P-450 induction.
@nl
P2093
P1476
Coadministration of lopinavir/ ...... gh cytochrome P-450 induction.
@en
P2093
Andrea Gaedigk
Angela D M Kashuba
Marjorie Robinson
Michael L Lim
Richard J Bertz
Sherene S Min
P304
P356
10.1097/00126334-200408150-00006
P407
P577
2004-08-01T00:00:00Z